Market Size (2016)
$1.06B
Vertical: HealthcareBase Year: 201611 Sections
Market Size (2016)
$1.06B
Projected (2023)
$2.31B
CAGR (2014–2023)
11.9%
Key Players
7+
Safety lancets are one of the widely used alternative device to obtain the blood samples. Lancets are receiving global recognition and acceptance due to its several convenient characteristics which gives them an edge over the traditional methods for vein puncture. Some of important features of the safety lancets are painless vein puncture, easy handling and safety while using. The major applications of the safety lancets are capillary blood micro sampling, cholesterol test, HBO and HIV screening test, blood group test, coagulation tests, allergy tests and many other blood based tests.
Safety lancets are introduced in 1994 by Medlance with the initiation button and T-shape cover over it. They are useful to avoid needle-stick injuries and infections. In United States alone in 2014, around 2.2 million people had chronic hepatitis B virus infection. (CDC, Viral Hepatitis - Hepatitis B Information, 2016). To reduce the prevalence of such blood borne infections, safety lancets are very helpful. Safety lancets can be further classified by their structural specifications such as Push Button Safety Lancets, Pressure Activated Safety Lancets and Side Button Safety Lancets. Companies like HTL-STREFA S.A. Medline Industries, Inc. and Sarstedt AG & Co are some of the major manufacturers of safety lancets.
Increasing awareness of Safety Lancet:
Rising prevalence of diabetic population, increased awareness for blood glucose monitoring device (homecare) and increased awareness of safety measures in order to avoid the infectious diseases are some of the significant factors of the increased awareness and use of lancets.
Production of Safety Lancet:
A large number of safety lancet manufacturers are from developing Asian countries such as China, India, Japan and Republic of Korea mainly because of the low labour cost and low R&D cost. China being one of the highly populated and technologically advanced developing countries, has a major number of lancets manufacturers. Some of the renowned Chinese Safety Lancet manufacturers are Guangzhou Improve Medical Instruments Co, Huang and KDL China. HTL Strefa and Sarstedt are two European companies which have marked their presence on the global level as a major manufacturer of Safety Lancets in the world.
The market for safety lancets is growing rapidly. Increasing prevalence of needle-stick injuries and rising awareness of safety lancet applications are the driving factors of the safety lancet market. The market for safety lancets by type is segmented into Push Button Safety Lancets, Pressure Activated Safety Lancets and Side Button Safety Lancets, in which Push Button Safety Lancets accounts for the largest market share in 2016 as there is a growing need for safe blood glucose test in hospitals and the growth of insulin users. Push Button Safety Lancets is projected to grow at the fastest CAGR of 12.28% during the forecast period from 2017-2023.
Additionally, the market is further segmented on the basis of end user and is bifurcated into Hospitals & Clinics, Diagnostic Canters and Pathology Laboratories, Home Diagnostics and others. Out of which hospital & clinics holds the largest market share among the all the end users. Diagnostic canters and pathology laboratories is the second largest segment in Global Safety lancets market, by End User as growing prevalence of diabetes around the globe, improving healthcare regulations for medical devices is driving the growth of the safety lancet market by end users. The global safety lancets market by end user is expected to reach USD 2,305.1 million in the year 2023 from USD 1,056.2 million 2016.
On the basis of region the market is segmented into North America, Europe, Asia-Pacific and Middle East and Africa. Europe region captured the largest market globally is expected to USD 1,032.7 million by 2023 as the growing demand and need for safe blood glucose tests in hospitals, clinics, diagnostics centers etc. and the growth of insulin users. In addition the European market is supported by increasing regulatory and safety standards in developed and developing markets. Asia-Pacific region is projected to be the fastest growing at a CAGR of 12.40% during the forecast period from 2017-2023.
The market in this report would cover market based on safety lancet types, end users and regions. The global market of lancets is dominated by several major players such as HTL-STREFA S.A, BD, Bayer, LifeScan, KDL China, Medline, Sarstedt and others.
The Safety Lancet Market market is projected to grow at a CAGR of 11.9% from 2014 to 2023.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSafety lancets are single-use gadgets/devices for narrow blood testing used by professionals in healthcare services. They are a necessary part to the sharps-injury aversion programs in hospitals, clinics, research centers, physicians’ offices and wherever both patients and experts need to feel safe. Needle-stick wounds and diseases can be avoided by utilizing Safety lancets. Some of the features of safety lancets are they are simple to use, they have color-coded product versions to meet specific blood sample applications and address the variety of patient skin types and simple and easy to handle.
Globally lancets are being utilized by patients who are affected by endocrine related complications, cardiovascular issues and many other issues. Lancets are being used for diabetes/glucose test, tests in infants, heel-stick screening tests, as well as for scarred emergency patients or severely burned patients.
The global market of safety lancets is growing rapidly because of the rising prevalence of diabetes and growing number of blood borne diseases across the globe. The global market of safety lancets is expected to reach USD 2,305.1 million in 2023 from USD 1,056.2 million in 2016 with a CAGR of 11.8 %.
The major players of the market are HTL Strefa, Sarstedt AG & Co., Terumo Corporation, BD, Guangzhou Improve Medical Instruments Co., Ltd and others. APAC region was the most benefited region due to the increased use of lancets, because of its huge population and lower labour cost.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2016
Historical Period
2014 – 2015
Forecast Period
2017 – 2023
Primary Interviews
150+
Historical data (2014–2016) and forecast period (2016–2023)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThe global safety lancet market consists of many major players. However there are some major players in the market which are F. Hoffmann-La Roche AG, Becton, Dickinson and Company, Terumo Medical Corporation, Guangzhou Improve Medical Technology Co., Ltd., HTL-STREFA S.A., Bayer Crop Science Limited and others. In terms of volume Asian countries like China will capture a large portion of the market, companies like Guangzhou IMPROVE MEDICAL Technology Co. Ltd, SteriLance Medical (Suzhou) Inc., and others are capturing a major portion of the market globally in terms of volume.
HTL-STREFA S.A. accounted for major market share of Global Safety Lancet Market, with nearly 48% of market share. The large share of the company is attributed to the high demand for safety lancet globally. Moreover this company has a strong sales and distribution network and the after sales services provided helped the company to play major role in the satisfaction of the customers. F. Hoffmann-La Roche AG accounts for approximately 20% which can be attributed to their product the ACCU-CHEK which has created the high demand of safety lancets in the market.
Bargaining Power of Suppliers
The suppliers in the global safety lancet industry are the developers and manufacturers of safety lancet. There are a high number of suppliers in the global safety lancet market thus leading to an averagely high amount of bargaining power in the market. Switching cost of these suppliers is average as suppliers tend to enter into long term associations with the safety lancet manufacturers. However, the Asian countries are consisting of large number of suppliers which offer these safety lancet at a relatively economical price. Due to moderately high bargaining power of suppliers the profit potential of the global safety lancet industry is reduced.
Bargaining Power of Buyers
The bargaining power of safety lancet buyers is moderate in the global safety lancet market, this is because of the large number of economical safety lancet providers in the industry. There are a large number of manufacturers or suppliers of safety lancet present in the industry which makes it a highly competitive market. Hence, availability of more number of manufacturers expands the selection arena of the sellers for the buyers, which leads to the increasing bargaining power.
Threat of New Entrants
Threat of new entrants is moderately low in the global safety lancet market. Any manufacturing company trying to enter the market is required to accept the mandatory regulatory standards as per the current reclassification of safety lancet by FDA. The Safety lancet market is also characterized by a reasonable degree of brand loyalty where establishing a brand name is difficult for newcomers. However, the cost involved in manufacturing setup is low to medium which discreetly comfort the new entrants to enter in the market easily.
Threat of Substitutes
Threat of substitutes in the global safety lancet market is very low. Buyer’s propensity to substitute is less due to low availability of substitutes in this market. In addition, the low degree of switching cost minimizes the threat of substitutes.
Intensity of Rivalry
The degree of competition in the global safety lancet market is considered to be moderate. The reserved degree of product differentiation among existing players increases the intensity of rivalry in the market. Safety lancet manufacturing companies are trying to develop products with high quality and enhanced safety in order to increase the demand for these products in developed countries and developing regions. To overcome the competition, players are engaged in developing process to lower their manufacturing cost.
Market estimates by geography (2023)
InsightEurope leads with $1.03B by 2023, while Asia Pacific is projected to grow fastest at a 12.4% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2014 | 2016 | 2023 | CAGR | SHARE |
|---|---|---|---|---|---|
| Middle East and Africa | $50.20M | $67.30M | $79.70M | 5.3% | 3% |
| North America | $302.20M | $533.20M | $843.00M | 12.1% | 37% |
| Asia Pacific | $122.00M | $218.50M | $349.60M | 12.4% | 15% |
| Europe | $366.80M | $650.60M | $1.03B | 12.2% | 45% |
| Total | $841.20M | $1.47B | $2.31B | 11.9% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$2.31B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Push Button Safety Lancets | $1.11B | 12.3% | 48% |
| Side Button Safety Lancets | $654.70M | 11.0% | 28% |
| Pressure Activated Safety Lancets | $535.30M | 12.1% | 23% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.

Analytical insights on Safety Lancet Market covering market dynamics, competitive landscape, and strategic outlook.
The Safety Lancet Market market is projected to reach $2.31B by 2023, growing at 11.9% CAGR. The Push Button Safety Lancets segment holds the largest share.
The global safety lancet market has been identified as one of the fastest growing industries, owing to the changing dynamics of the legal and regulatory framework and the intense competitive rivalry among a plethora of public companies. The following segment will discuss the key market driving and restraining forces.
Developing contagious and non-contagious diseases can be characterized as diseases that have recently appeared in a population or have existed however are quickly expanding in incidence or geographic range. Hantavirus pulmonary syndrome, HIV/AIDS, Lyme disease, hemolytic uremic syndrome among others.
Incidence of contagious diseases is increasing rapidly on a global level. According to WHO, it has been calculated that, infectious diseases for example plaque which is also known as black death has an estimated 50 million deaths in the 14th century, this infectious disease can be a serious disease if not treated, this disease has a case fatality ratio of around 30%-60%, as of 2013 there were 783 cases worldwide which includes 126 deaths.
Thus with growing incidence of contagious and non-contagious diseases the demand for common tests such as blood tests, urine tests etc. would increase and devices used for these tests will increase, as a result there will be a lift in the global market of lancets.
Every medical process involves potential benefits to the patient as well as possible risks. These risks must be examined whenever transfusion of blood or blood components is considered. Having an allergic reaction to the donated blood is an unusual problem of blood transfusion. However in 2013 there were approximately 320 cases of allergic reactions after blood transfusion in the UK, these allergic reactions are caused due to the body’s immune system which reacts to substances such as proteins in the donated blood. The reactions of the allergic reactions are usually mild but can be harmful if not attended with proper medical care.
Some other risks associated with blood transfusion are anaphylaxis, Lung injury, fluid overload, bacterially contaminated blood, Haemolytic reactions and viral contaminated blood.
Thus with such risks associated with blood transfusion people may hesitate to go through the process or use related products in the blood transfusion procedure like blood lancets, safety lancets, etc. Therefore such risk associated factors may restrain the growth of global safety lancet market.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 104 companies operating in the Safety Lancet Market market, including revenue, employee count, and market positioning where available.
Showing 104 of 104 companies
Company Headquarters: Tokyo, Japan Founded: 1921 Workforce: 25,000 Company Working: Terumo Medical Corporation delivers innovative health solutions and provides breakthrough solutions and technologies. The company is involved in manufacturing and sales of medical products and equipment, such as pharmaceuticals, nutritional food supplements, disposable medical devices, vascular grafts, and blood glucose monitoring systems, among others. It has a market presence in over 160 countries in the world. It operates its business through three segments, namely, cardiac and vascular company, blood management company, and general hospital company. Terumo Interventional Systems (TIS), a division of Terumo Medical Corporation, is a market leader in minimally invasive entry site management, lesion access, and interventional technologies. TIS offers a complete, solution-based product portfolio used in advanced coronary, peripheral endovascular and urological treatments with strategic initiatives in Transradial Access, Complex Coronary Intervention, Peripheral Artery Disease and Embolotherapy.
HTL-STREFA S.A. is a Poland based medical device company which was incorporated in the year 1995. It is world’s leading medical device company that develops manufactures and sells safety lancets, personal lancets, and pen needles for insulin injection. They have a wide range of products which includes safety lancets, pen needles, personal lancets and lancing devices. They have an experienced team of employees that continuously improvise on their strategy for analysing and updating their products. They are implementing improvements and launching new solutions to meet the changing needs of both patients and health care professionals. Some of the competitors of HTL STREFA are Owen Mumford Ltd., SHL Group, IDEO LLC, and Victoza among others. HTL-STREFA S.A. is headquartered in Poland having the employee strength of more than 1170 spread over more than 80 countries around the world. The company generated net sales of 68 million EURO in 2015.
Incorporated in 1996 and headquarters in United States, Guangzhou Improve Medical Instruments Co., Ltd which is also referred to as Improve Medical, is a global company which provides appropriate products, services and technologies in the field of clinical laboratories and clinical nursing. The company is one of the leading companies in domestic high-end market and one of the leading suppliers in the field of Evacuated Blood Collection System in the world. The major products of the company include products like Improvacuter, Impromini, Improswab, Impronurse, Longx etc. The company operates in more than 90 countries globally and has a work force of around 1000 employees.
Established in 1961 and headquarters in Germany, Sarstedt AG & Co is one of the world’s largest manufacturers and developers of medical and laboratory equipment. The company aims to provide its customers with highly efficient and high quality products. Sarstedt AG & Co involves 31 sales organizations in Europe and 13 production sites in North America, Europe and Australia. The company has an employee work force of around 2500 employees.
Coty is a fragrance-led global beauty company and, by its own description, one of the world's largest beauty groups, with FY2026 net revenues of USD 5.81bn split roughly two-thirds Prestige (licensed and owned luxury fragrance, prestige cosmetics and skincare — Burberry, Hugo Boss, Calvin Klein, Chloé, Marc Jacobs, Davidoff, Kylie Cosmetics, Gucci until mid-2027) and one-third Consumer Beauty (mass color cosmetics such as CoverGirl, Rimmel, Max Factor and Sally Hansen; mass fragrance; and Brazilian body care). Its core competitive asset is an end-to-end fragrance platform — licensing, innovation, ~81% in-house manufacturing and global prestige distribution — that has produced blockbuster franchises such as Burberry Goddess. After five years of deleveraging under Sue Nabi, Coty entered 2026 in a reset: revenue and margins are declining, the Gucci licence exits a year early, mass color and Brazil are under strategic review, and new interim leadership is executing a "Coty.Curated" focus-and-simplify framework with leverage of 3.4x. --- **Company's own description (paraphrased from FY2026 10-K, Item 1).** Coty describes itself as one of the world's largest beauty companies with an iconic brand portfolio across fragrance, color cosmetics, and skin and body care. It states that it is focused on leveraging its leadership position and capabilities in global fragrances to fuel expansion, strengthening its presence in a limited number of structurally profitable and growing categories, and prioritising growth channels such as e-commerce and Travel Retail. Under the Coty.Curated framework it emphasises fewer, bigger initiatives, marketing sufficiency, supply reliability, consumer advocacy, more productive innovation and portfolio choices, a return to market-share growth, and AI-powered, data-driven operations. It is also evaluating its central organisation, manufacturing and asset base to resize after the Gucci exit. **What the company does.** Coty designs, manufactures (≈81% in-house, ≈19% via third-party manufacturers in FY2026), markets and distributes beauty products. The essential oils in its fragrances are generally sourced from specialist fragrance houses; Coty owns the brand development, juice selection/briefing, bottle and packaging design, filling and assembly, marketing and commercial execution. Principal raw materials are essential oils, alcohols and specialty chemicals (10-K FY2026). **Business model and revenue model.** **Value-chain position.** Coty sits between ingredient suppliers (fragrance houses, alcohol and packaging suppliers) and retailers. Its economic moat lies in (i) licence portfolio scale in prestige fragrance, (ii) innovation and launch capability (brief-to-shelf), and (iii) owned manufacturing in the U.S., Europe and Brazil. It is structurally exposed to licensors (who own the trademarks) and to concentrated retailers (Sephora, Ulta, Douglas, Walmart, drug chains, travel-retail operators). **End markets.** Prestige fragrance (core), prestige cosmetics (Kylie Cosmetics, Marc Jacobs Beauty, Gucci Beauty until FY2027), prestige skincare (Lancaster, philosophy), mass color cosmetics, mass fragrance and mists, mass skin & body care (concentrated in Brazil). **Independent characterisation.** Coty is effectively two businesses with very different economics: a high-quality, licence-dependent prestige fragrance franchise generating ~20% adjusted EBITDA margins (Prestige FY2026 adjusted EBITDA margin 20.5% per Q4 FY2026 call), and a structurally challenged mass color cosmetics/Brazil business whose segment adjusted EBITDA margin collapsed to the low single digits in FY2026 (derived). The 2025–2026 strategic actions (Wella exit, Gucci monetisation, Consumer Beauty review) are converting Coty into a narrower fragrance pure-play with lower leverage but higher licence concentration.
Codexis is a Redwood City-based enzyme engineering company in the middle of a deliberate transition. It is moving from a diversified "protein engineering" platform company, whose revenue was historically dominated by custom biocatalysts for small-molecule drug manufacturing, toward a focused provider of enzymatic manufacturing solutions for oligonucleotide therapeutics, chiefly siRNA/RNAi. Its proprietary CodeEvolver® directed-evolution platform underpins two businesses. The first is a cash-generating but lumpy pharma biocatalysis franchise, anchored by long-standing relationships with Merck & Co. and other large pharmaceutical companies, which supports about 14 commercial products. The second is the pre-commercial ECO Synthesis® Manufacturing Platform, which aims to replace solid-phase phosphoramidite chemistry with enzymatic routes, together with a commercially launched dsRNA ligase. The company is a sub-$200 million market capitalization micro-cap and remains loss-making. It has about $80 million of pro forma liquidity, a $40 million term loan, and guidance for FY2026 revenue of $72–76 million. --- ### Company's own description (FY2025 10-K / standard press-release boilerplate, paraphrased) Codexis describes itself as a leading provider of enzymatic solutions for efficient, scalable therapeutics manufacturing. It discovers, develops and improves high-performance enzymes using its proprietary CodeEvolver® technology. According to the company, its enzymes address real-world problems in small-molecule pharmaceutical manufacturing and nucleic acid synthesis. Codexis is developing the ECO Synthesis® Manufacturing Platform to enable scaled manufacture of RNAi therapeutics through an enzymatic route. It says its enzymes can raise yields, cut energy use and waste, improve manufacturing efficiency, and increase sensitivity in genomic and diagnostic applications (Codexis Q4 FY2025 and Q2 FY2026 press releases). The FY2025 10-K states that headquarters is both the administrative centre and the centre of research, development and business operations, with limited internal manufacturing capacity. In-house manufacturing produces Codex® biocatalyst panels and kits, plus enzymes for customers' pilot-scale and clinical production. The ECO Synthesis Innovation Lab sits inside headquarters and is designed to supply non-GMP material in quantities that support customers' preclinical development. The company expects to partner with CDMOs for bulk GMP-grade siRNA production for clinical supply and beyond. ### Independent characterization Codexis is best understood as a technology-licensing and specialty-enzyme supplier whose economics depend on a small number of very large pharmaceutical relationships. In FY2025 a single customer accounted for about 51% of total revenue (FY2025 10-K, "Customers"). Given the $37.8 million Merck agreement recognised mainly in Q4 FY2025, that customer is almost certainly Merck. The business model has three monetization layers. The first layer is product revenue: sales of engineered enzymes (biocatalysts), pharmaceutical intermediates, Codex® biocatalyst screening panels and kits, and, increasingly, ligase and ECO enzyme supply. Product revenue is driven by customers' commercial manufacturing schedules and is therefore volatile quarter to quarter. Product gross margin has improved structurally, from 56% in FY2024 to 64% in FY2025 and 71–73% in Q1–Q2 FY2026. Management attributes this to a shift toward higher-margin products and the run-off of lower-margin legacy products. The second layer is research and development revenue: CodeEvolver platform licence fees, technology-transfer payments, milestone payments, feasibility and evaluation fees, and ECO Synthesis manufacturing services (for example, the low-seven-figure contract to supply 50 g of siRNA). In FY2025 R&D revenue exceeded product revenue for the first time in the period analysed ($44.4 million vs. $26.0 million). The main reason was the Merck technology transfer. The third layer is royalty and contingent consideration from out-licensed or divested assets. These include the Nestlé Health Science CDX-7108 sale (up to $45 million in milestones plus a single-digit royalty), the Aldevron HiCap RNA polymerase licence (milestones and royalties), and the Roche dsDNA ligase licence (upfront and technical milestones). These are largely back-ended and uncertain. **Value-chain position.** Codexis sits upstream of drug-substance manufacturing. It supplies process technology (enzymes and the know-how to use them) to innovator pharma companies, generic manufacturers and CDMOs, which then run the commercial processes. In the oligonucleotide chain it is trying to move one step downstream. Its planned ECO GMP Manufacturing Center would make siRNA material for preclinical and Phase 1 supply. This hybrid "tool supplier plus early-phase manufacturer" model is a new risk profile for the company. **Customer types:** large innovator pharma (Merck, plus historically Pfizer, GSK and Novartis); high-growth RNAi biotech innovators (unnamed counterparties in 2025–2026 agreements); CDMOs (Bachem, Nitto Denko Avecia, Axolabs); and life-science tools companies (Roche, Aldevron, seqWell). **End-markets served:** small-molecule API manufacturing (biocatalysis); oligonucleotide/RNAi therapeutic manufacturing; and, as a residual licensing stream, life-science tools and genomics reagents. ### Revenue model mix (FY2021–FY2025) *Sources: Q4 FY2022 press release (FY2021–FY2022 PAXLOVID figures); FY2023 10-K (product revenue); Q4 FY2023 press release (ex-PAXLOVID revenue of $62.0 million implies about $8.1 million PAXLOVID-related revenue in FY2023, largely the release of deferred Pfizer fees); Q4 FY2025 8-K Exhibit 99.1 (FY2024–FY2025). Shares are computed.*
10 interactive charts drawn from the Safety Lancet Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Global Safety Lancet Market Germany, Spain, France, United Kingdom, Italy and Rest Of Europe By Country
Global Safety Lancet Market China, India, Japan, South Korea and Rest Of Asia Pacific By Country
Global Safety Lancet Market United States and Canada Of North America By Country
Global Safety Lancet Market Rest Of Middle East And Africa, Saudi Arabia, UAE and Egypt Of Middle East And Africa
Global Safety Lancet Market By Region
Safety Lancet Market Europe By Country
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Mn)